Streptococcus pneumoniae serotype 4 capsular polysaccharide-specific B-cell receptor (Sp4 CPS-specific BCR)

Streptococcus pneumoniae serotype 4 capsular polysaccharide-specific B-cell receptors (BCRs) and antibodies are critical components of the adaptive immune system's defense against invasive pneumococcal disease (Source: PubMed PMC3531071). These receptors, located on the surface of B lymphocytes, specifically recognize and bind to the repeating oligosaccharide units of the serotype 4 capsule, a major virulence factor of the bacterium (Source: PubMed 22948246). Upon activation, these B cells proliferate and differentiate into plasma cells that secrete soluble antibodies, primarily of the IgG2 and IgM subclasses in humans. These antibodies facilitate the clearance of the pathogen through opsonophagocytosis, where they coat the bacterial surface and promote ingestion by macrophages and neutrophils (Source: Janeway's Immunobiology). In the context of pharmaceutical development, these BCRs and antibodies are the primary targets of pneumococcal conjugate vaccines (PCVs) and polysaccharide vaccines (PPSVs), which aim to elicit a robust and long-lasting memory response (Source: FDA). Understanding the structural basis of this interaction is essential for designing next-generation vaccines that provide broader coverage and overcome challenges such as serotype switching and replacement.

Other names

Anti-Sp4 antibodySerotype 4 pneumococcal capsular polysaccharide antibodySp4-specific B-cell receptorPneumococcal serotype 4 antibody

Binding of the vaccine's capsular polysaccharide antigen to the B-cell receptor, which triggers B-cell activation, proliferation, and differentiation into plasma cells that secrete protective antibodies (Source: PubMed 22948246).